Elute, Inc. is an emerging leader in the development of novel, drug eluting devices designed for controlled and sustained release of drugs. Elute’s initial product candidate is EP Granules with Tobramycin, a bone void filler (BVF) that provides clinically relevant and unprecedented 8-week delivery of an antibiotic while growing new bone and clearing bone infection. This product has recently received authorization from the US Food and Drug Administration (FDA) to use its EP Granules with Tobramycin TM in a pivotal clinical trial. EP Granules with Tobramycin is a synthetic calcium-salt resorbable bone void filler that is designed to provide 8-week delivery of an antibiotic in a local targeted region while allowing growth of new bone. Additional applications of the device, when cleared, include treatment of bone infections in a variety of orthopedic indications including large joint (hip and knee) reconstruction, spinal fusion, trauma, foot reconstruction, as well as craniomaxillofacial and oncological applications.
Elute is led by a seasoned management team, attracted board members with significant domain experience with their senior executive roles in the largest orthopedic device companies in the world and key opinion leaders to serve on its clinical advisory board.